Form 4: Esperion General Counsel Sells Shares for Tax Obligation
Insider Transaction Report
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 1,248 shares of common stock to cover tax obligations related to vested restricted stock units.
Summary
- Benjamin Looker, General Counsel of Esperion Therapeutics, Inc. (ESPR), reported a sale of company common stock.
- The transaction involved the disposition of 1,248 shares of common stock.
- The shares were sold at a price of $2.6245 per share.
- The sale was executed on October 17, 2025, as part of a pre-arranged Rule 10b5-1(c) plan.
- The purpose of the sale was to satisfy tax obligations arising from the vesting of restricted stock units.
- Following this transaction, Benjamin Looker directly beneficially owns 392,422 shares of Esperion Therapeutics common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine insider sale for tax purposes, indicating neither positive nor negative sentiment towards the company's fundamentals. It's a neutral event.
Risks
- Reporting persons retain full responsibility for compliance with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, even when using a power of attorney for filing.
- The reporting person agrees to indemnify the attorney-in-fact and the Company against any demand, damage, loss, cost, or expense arising from false or misleading information provided by the reporting person to the attorney-in-fact.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This insider transaction is a routine event for publicly traded companies, where executives often sell shares to cover tax liabilities upon the vesting of equity awards. It does not reflect broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Benjamin Looker granted a Limited Power of Attorney to Sheldon Koenig and Richard Bartram to execute and file SEC forms (Form ID, 3, 4, 5, Schedule 13D) on his behalf as an officer and/or director of Esperion Therapeutics, Inc. | 2021-12-13 | Streamlines the process for insider reporting compliance for Benjamin Looker, ensuring timely and accurate filings with the SEC. It clarifies that the reporting person retains ultimate responsibility for compliance. |
Stakeholder Impact
- Shareholders: The sale of a small number of shares for tax purposes by an executive is a routine event and is unlikely to have a material impact on shareholder value or perception.
- Employees: No direct impact on employees is indicated by this filing.
- Management: The Power of Attorney streamlines compliance for the General Counsel, allowing designated individuals to handle SEC filings on his behalf.
Key Dates
| Date | Description |
|---|---|
| 2021-12-13 | Date Benjamin Looker executed the Limited Power of Attorney. |
| 2025-10-17 | Date of the reported transaction (sale of common stock). |
| 2025-10-20 | Date the Form 4 was signed and filed with the SEC. |
Recommendation
holdThis Form 4 reports a routine insider sale by the General Counsel to cover tax obligations on vested restricted stock units. Such transactions are common and do not typically reflect a change in the executive's outlook on the company's prospects. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation for current investors.
Keywords
Esperion Therapeutics, ESPR, Insider Trading, Form 4, Benjamin Looker, General Counsel, Stock Sale, Tax Obligation, Restricted Stock Units, RSU, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.